Search

(Bloomberg) -- The U.K. is considering relaxing rules around the use of artificial intelligence in its post-Brexit data regime, a move that would mark a break from the European Union. The right to a human review is covered by Article 22 of the EU's data protection regime, which was transposed into U.K. law after Brexit. [Extracted from the article]

(Bloomberg) -- UK lawmakers have urged regulators to take action to head off "significant risks" posed to workers by the boom of artificial intelligence programs including ChatGPT. The report from backbencher members of Parliament from the main political parties suggests that the rapid development of AI will face intense scrutiny from regulators in the coming years as technology threatens to transform work. [Extracted from the article]

In a boost for Sunak, Weis said the UK is ahead of the curve when looking at AI compared to some European peers. (Bloomberg) -- The UK has about three years to come up with rules to reassure people about artificial intelligence before wrenching changes in the way work is done unleashes the potential for social unrest, an industry expert said. [Extracted from the article]

Instead, the ugliest potential outcome would probably be a proxy fight, with Elliott asking investors to support a slate of new directors for GSK's board. Elliott doesn't have an issue with Walmsley emerging as the best candidate but wants the company, led by directors with pharmaceutical and science experience, to go through the process to prove it, according to people with knowledge of the matter. Keywords: AZN@LN; EBAY; GSK@LN; ME; MGGT@LN; MRK@GR; MRW@LN; ROG@SW; AI; ALLTOP; BASIC; BUSINESS; CMD; COS; DRG; EUROPE; EURTOP; GENTOP; HEA; INDUSTRIES; LAW; MARKETS; MED; METMNG; NORTHAM; STK; TEC; TMT; TOP; UK; US; WORLD; WWTOP; WWTOPAM; WWTOPAS; WWTOPEU EN AZN@LN EBAY GSK@LN ME MGGT@LN MRK@GR MRW@LN ROG@SW AI ALLTOP BASIC BUSINESS CMD COS DRG EUROPE EURTOP GENTOP HEA INDUSTRIES LAW MARKETS MED METMNG NORTHAM STK TEC TMT TOP UK US WORLD WWTOP WWTOPAM WWTOPAS WWTOPEU GSK's Emma Walmsley is seeking to survive a challenge from Elliott Investment Management, the activist that no CEO wants to hear from. Many of the views Elliott heard from other GSK investors were the ones its executives expected: that the company wasn't producing enough big-hitting new drugs, or making bets bold enough to differentiate itself from other drugmakers. [Extracted from the article]

Drug discovery startup BenevolentAI has begun a major hiring spree, as it seeks to take advantage of the current boom in the U.K.'s artificial intelligence and machine learning sector. The London-based startup, valued at $1.7 billion according to data firm CB Insights, is seeking to hire 50 new staff across AI, data science and bioinformatics, software engineering and medicinal science. [Extracted from the article]